The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment
Diabetic Medicine · 2023-03 · 40 (3)
DOI: 10.1111/dme.15021 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetic Medicine, online erschienen am 23.12.2022. Verfasst von Ilker Tasci. Beteiligte Einrichtung: Department of Internal Medicine, Gulhane Faculty of Medicine & Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Gulhane Faculty of Medicine & Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.
ORCID-Profile: Ilker Tasci
Zitieren
APA
Tasci, I. (2023). The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment. Diabetic Medicine, 40(3). https://doi.org/10.1111/dme.15021
Vancouver
Tasci I. The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment. Diabetic Medicine. 2023;40(3). doi:10.1111/dme.15021
BibTeX
@article{Tasci2023,
author = {Tasci, Ilker},
title = {The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment},
journal = {Diabetic Medicine},
year = {2023},
volume = {40},
number = {3},
doi = {10.1111/dme.15021}
}
EUVIMED